G. Morgan

发表

S. Davis, F. Davies, J. Child, 1997, Molecular pathology : MP.

Autoimmune thrombocytopenia in Waldenström's macroglobulinemia

G. Morgan, A. Jack, R. Owen, 2001, American journal of hematology.

Serum free light chains for monitoring multiple myeloma

M. Drayson, G. Mead, A. Bradwell, 2004, British Journal of Haematology.

Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia.

P. Evans, S. Kinsey, R. Owen, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

Y. Le Bihan, C. Wardell, N. Weinhold, 2021, Leukemia.

Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study.

N. Russell, J. Davis, A. Haynes, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isotype class switching and the pathogenenesis of multiple myeloma

G. Pratt, J. Fenton, G. Morgan, 2002, Hematological oncology.

Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma

J. Child, G. Pratt, J. Fenton, 1998, Hematological oncology.

THE USE OF BIOLOGICAL VARIABLES TO PREDICT OUTCOME IN MULTIPLE MYELOMA

F. Davies, A. Jack, G. Morgan, 1997, British journal of haematology.

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect

P. Johnson, A. Burnett, S. Rule, 2006, Bone Marrow Transplantation.

Quantitative PCR of the immunoglobulin heavy chain gene using genomic DNA

S. Kinsey, G. Morgan, C. Shiach, 1996, British journal of haematology.

Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve

R. Johnson, G. Pratt, G J Morgan, 2001, British journal of haematology.

The development of targeted chemotherapy for CNS lymphoma—a pilot study of the IDARAM regimen

G. Morgan, B. Mcverry, J. Child, 2004, Cancer Chemotherapy and Pharmacology.

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.

S. Barrans, G. Morgan, J. Child, 2001, American journal of clinical pathology.

Assessing response of myeloma bone disease with diffusion-weighted MRI.

G. Morgan, D. Collins, N. deSouza, 2012, The British journal of radiology.

Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma

J. Collins, S. Richards, G. Pratt, 2001, British journal of haematology.

Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests

S. Maclennan, J. Child, T. Perren, 2000 .

MRC Myeloma IX: Preliminary Results from The Intensive Pathway Study

W. Gregory, M. Drayson, F. Ross, 2009 .

Microsatellite instability in follicle centre cell lymphoma

S. Barrans, P. Johnson, P. Evans, 1996, British journal of haematology.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

Caleb K. Stein, O. Stephens, B. Barlogie, 2017, Nature Communications.

In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA‐5 and CD45 expression

S. Barrans, J. Child, S. Richards, 2001, British journal of haematology.

Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Position statement on the use of bortezomib in multiple myeloma

G. Morgan, J. Cavenagh, J. Cavenagh, 2008, International journal of laboratory hematology.

Comparison of fluorescent consensus IgH PCR and allele‐specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL

G. Morgan, P. Evans, M. Potter, 1997, British journal of haematology.

Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin.

G. Morgan, S. Rollinson, P. Croucher, 2003, Immunity.

Assessment of IgH PCR strategies in multiple myeloma.

G. Morgan, P. Evans, J. Child, 1996, Journal of clinical pathology.

Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection

G. Morgan, N. Russell, P. Evans, 1996, Clinical molecular pathology.